Panacea Biotec Ltd
NSE: PANACEABIO BSE: 531349
Panacea Biotec Ltd (PANACEABIO) is a Diversified company listed on NSE: PANACEABIO | BSE: 531349. With a market cap of ₹2,482 Cr and ROCE of 2.14%, ROE of 4.76%, it operates in the Indian Diversified sector.
₹405
52W: ₹292 — ₹555
PE 0 · Book ₹47.6 · +751% vs bookMarket Cap₹2,482 Cr
Stock P/E—Price to Earnings
ROCE2.14%Return on Capital
ROE4.76%Return on Equity
Div. Yield0%Face Value ₹1
Weaknesses
- −Stock is trading at 8.57 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of -10.3% over last 3 years.
- −Company might be capitalizing the interest cost
Shareholding Pattern
Promoters72.48%
FIIs1.6%
DIIs1.96%
Public23.96%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.47% | 72.87%▼0.6 | 72.49%▼0.4 | 72.48%▼0.0 | 72.48% | 72.48% | 72.48% | 72.48% |
| FIIs | 0.26% | 0.37%▲0.1 | 0.38%▲0.0 | 1.16%▲0.8 | 0.79%▼0.4 | 1.06%▲0.3 | 1.36%▲0.3 | 1.6%▲0.2 |
| DIIs | 1.07% | 1.16%▲0.1 | 1.16% | 1.49%▲0.3 | 1.52%▲0.0 | 1.8%▲0.3 | 1.85%▲0.1 | 1.96%▲0.1 |
| Public | 25.21% | 25.6%▲0.4 | 25.96%▲0.4 | 24.86%▼1.1 | 25.2%▲0.3 | 24.65%▼0.6 | 24.31%▼0.3 | 23.96%▼0.3 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94.59 | 95.23 | 80.37 | 56.88 | 76.64 | 108.43 | 67.9 | 112.25 | 90.81 | 99.31 |
| Expenses | 84.63 | 88.59 | 89.61 | 67.37 | 69.9 | 93.04 | 86.47 | 115.27 | 104.51 | 100.69 |
| Operating Profit | 9.96 | 6.64 | -9.24 | -10.49 | 6.74 | 15.39 | -18.57 | -3.02 | -13.7 | -1.38 |
| OPM % | 10.53% | 6.97% | -11.5% | -18.44% | 8.79% | 14.19% | -27.35% | -2.69% | -15.09% | -1.39% |
| Net Profit | 3.2 | 0.43 | -1.37 | -13.78 | 1.29 | 9.65 | -12.39 | -6.7 | -15.64 | -7.36 |
| EPS ₹ | 0.52 | 0.07 | -0.22 | -2.25 | 0.21 | 1.57 | -2.02 | -1.09 | -2.55 | -1.2 |
AI Insights
Revenue Trend
TTM revenue at ₹370Cr, up 19.4% YoY. OPM at -10%.
Debt Position
Borrowings at ₹280Cr. Debt-to-equity ratio: 0.98x. Moderate leverage.
Capex Cycle
CWIP at ₹97Cr (22% of fixed assets). Significant capex underway — growth runway building.
Institutional Flow
DIIs: 1.96% (+1.42pp change). FIIs: 1.6% (+1.38pp change). Promoters hold 72.48%.
Margin & Efficiency
ROCE improving from -9% (Mar 2014) to -2% (Mar 2025). Working capital days: -141.
Recent Announcements
- Details Of Shares Dematerialized During April 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 7 May - No shares dematerialized in April 2026; total demat shares remained 6,11,04,526.
- Intimation Of Fire Incident At Oncology Facility Of The Company'S Wholly Owned Subsidiary, Panacea Biotec Pharma Limited At Baddi, Himachal Pradesh 30 Apr - Fire at PBPL’s Baddi oncology QC lab on April 30, 2026 temporarily disrupts operations 5–7 days.
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 30 Apr - ITAT allowed Panacea Biotec’s appeal, cancelling ₹9.16 crore demand for AY2020-21.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Apr - Newspaper copies regarding notice intimating the investors about the opening of Special Window for Transfer and Dematerialisation of physical shares, in accordance with SEBI Circular …
- Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 11 Apr - Panacea Biotec received CMSS LOA for Td vaccine supply worth INR 20.79 crore from Sep/Oct 2026 to Nov/Dec 2028.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse